Author(s):
Ruchita S. Patil, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar
Email(s):
azamph46@gmail.com
DOI:
10.52711/2231-5691.2024.00060 
Address:
Ruchita S. Patil*, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar
Department of Pharmaceutics P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra - 425409, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2024
ABSTRACT:
One of the earliest recognized medical disorders, kidney stone disease still has unanswered questions on how it starts and progresses. The precise mechanisms behind the production of stones remain enigmatic, despite major technological improvements in recent decades leading to a variety of theories and surgical techniques. Three different fundamental pathways for kidney stone production have been identified by research, including observations made by the authors and other organizations. Intrarenal crystal precipitation is primarily caused by urinary supersaturation and crystallization. Randall's plaques are a source of stones composed of calcium oxalate. Furthermore, sex hormones may be important in the development of nephrolithiasis, indicating possible targets for novel therapies that block the creation of stones. Nephrolithiasis, or urolithiasis, is another name for kidney stone disease (KSD), which is a worldwide health concern that affects people in both developed and poor countries. With a high recurrence rate after stone removal, its frequency is still on the rise. To lessen the financial and physical effects of KSD, preventive actions are necessary even with the availability of excellent therapies. Preventing kidney stone formation requires an understanding of the etiology and risk factors, such as decreased urine production and dehydration.
Cite this article:
Ruchita S. Patil, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar. Kidney Stone: Mechanism of Formation and its Prevention A Review. Asian Journal of Pharmaceutical Research.2024; 14(4):381-6. doi: 10.52711/2231-5691.2024.00060
Cite(Electronic):
Ruchita S. Patil, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar. Kidney Stone: Mechanism of Formation and its Prevention A Review. Asian Journal of Pharmaceutical Research.2024; 14(4):381-6. doi: 10.52711/2231-5691.2024.00060 Available on: https://asianjpr.com/AbstractView.aspx?PID=2024-14-4-6
REFERENCES:
1. Allison MJ, Sidhu H, et al. Materials and methods for treating or preventing oxalate-related disease. United States patent 2004.
2. Romero V, Akpinar H and Assimos DG: Kidney stones: A global picture of prevalence, incidence, and associated risk factors. Rev Urol . 2010; 12: e86‑e96.
3. Morgan MS and Pearle MS: Medical management of renal stones. BMJ 352: i52, 2016.
4. Zeng G, Mai Z, Xia S, Wang Z, Zhang K, Wang L, Long Y, Ma J, Li Y, Wan SP, et al: Prevalence of kidney stones in China: An ultrasonography based cross‑sectional study. BJU Int. 2017; 120: 109‑116.
5. Eisner BH and Goldfarb DS: A nomogram for the prediction of kidney stone recurrence. J Am Soc Nephrol. 2014; 25: 2685‑2687.
6. Ziemba JB and Matlaga BR: Epidemiology and economics of nephrolithiasis. Investig Clin Urol, 2017; 58: 299‑306.
7. Brikowski TH, Lotan Y and Pearle MS: Climate‑related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci USA. 2008; 105: 9841‑9846.
8. Abeywickarama B, Ralapanawa U and Chandrajith R: Geoenvironmental factors related to high incidence of human urinary calculi (kidney stones) in Central Highlands of Sri Lanka. Environ Geochem Health. 2016; 38: 1203‑1214.
9. Wang Z, Zhang JW, Zhang Y, Zhang SP, Hu QY and Liang H: Analyses of long non‑coding RNA and mRNA profiling using RNA sequencing in calcium oxalate monohydrate‑stimulated renal tubular epithelial cells. Urolithiasis. 2019; 47: 225‑234.
10. Parmar MS: Kidney stones. BMJ. 2004; 328: 1420‑1424.
11. Ye Z, Zeng G, Yang H, Li J, Tang K, Wang G, Wang S, Yu Y, Wang Y, Zhang T, et al: The status and characteristics of urinary stone composition in China. BJU Int. 2020; 125: 801‑809.
12. Aggarwal K.P., Narula S., Kakkar M. and Tandon C.: Nephrolithiasis: Molecular mechanism of renal stone formation and the critical role played by modulators. Biomed Res Int. 2013: 292953, 2013.
13. Fisang C, Anding R, Müller SC, et al. Urolithiasis-anInterdisciplinary Diagnostic, Therapeutic and Secondary Preventive Challenge. Dtsch Arztebl Int. 2015; 112: 83-91.
14. Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010; 25: 831-41.
15. Gupta S, Shamsher SK. Kidney stones: Mechanism of formation, pathogenesis and possible treatments. J Biomol Biochem. 2018; 2(1): 1-5.
16. Barbasa C, Garciaa A, Saavedraa L, et al. Urinary analysis of nephrolithiasis markers. J Chromatogr B. 2002; 781: 433-55.
17. Han H, Segal AM, Seifter JL, et al. Nutritional Management of Kidney Stones (Nephrolithiasis). Clin Nutr Res. 2015; 4: 137-52.
18. Tiwari A, Soni V, Londhe V, et al. An overview on potent Indigenous herbs for urinary tract infirmity: urolithiasis. Asian J Pharm Clin Res. 2012; 5: 7-12.
19. Mirian AB, Ita PH, Schor N, et al. Phyllanthus niruri as a promising alternative treatment for nephrolithiasis. International Braz J Urol. 2010; 36: 657-64.
20. Aray P, Pandey S, Verma V, et al. Kidney stone formation and use of medicinal plants as anti-urolithiatic agents. UJPSR. 2017; 2: 43-48.
21. Evan AP, Lingeman JE, Coe FL, et al. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 2005; 67: 576-91.
22. Hamid M, Mohammad MN, Ghanea L, et al. Evaluation of theRaphanus sativus effect on urinary pH. J of Res in Med Sc. 2007; 12: 58.
23. Aggarwal A, Tandon S, Singla SK, et al. Diminution of oxalate induced renal tubular epithelial cell injury and inhibition of calciumoxalate crystallization in vivo by aqueous extract of Tribulu terrestris. International Braz J Urol. 2010; 36: 480-9.
24. Combest W, Newton M, Combest A, et al. Effects of herbal supplements on the kidney. Urol Nurs. 2005; 25: 381-6.
25. Umashankar D, Chandra R, Chawla AS, et al. High-pressure liquid chromatographic determination of bergenin and (+)-afzelechin from different parts of Paashaanbhed (Bergenia ligulata yeo). Phytochem Anal. 1999; 10: 44-7.
26. Daudon M, Frochot V, Bazin D and Jungers P: Drug‑induced kidney stones and crystalline nephropathy: Pathophysiology, prevention and treatment. Drugs. 2018; 78: 163‑201.
27. Thongboonkerd V: Proteomics of crystal‑cell interactions: A model for kidney stone research. Cells. 2019; 8: 1076.
28. Fong‑Ngern K, Sueksakit K and Thongboonkerd V: Surface heat shock protein 90 serves as a potential receptor for calcium oxalate crystal on apical membrane of renal tubular epithelial cells. J Biol Inorg Chem. 2016; 21: 463‑474.
29. Wiener SV, Ho SP and Stoller ML: Beginnings of nephrolithiasis: Insights into the past, present and future of Randall's plaque formation research. Curr Opin Nephrol Hypertens. 2018; 27: 236‑242.
30. Vezzoli G, Macrina L, Magni G and Arcidiacono T: Calcium‑sensing receptor: Evidence and hypothesis for its role in nephrolithiasis. Urolithiasis. 2019; 47: 23‑33.
31. Farmanesh S, Chung J, Sosa RD, Kwak JH, Karande P and Rimer JD: Natural promoters of calcium oxalate monohydrate crystallization. J Am Chem Soc. 2014; 136: 12648‑12657.
32. Daudon M, Bazin D and Letavernier E: Randall's plaque as the origin of calcium oxalate kidney stones. Urolithiasis. 2015; 43(Suppl 1): S5‑S11.
33. Winfree S, Weiler C, Bledsoe SB, Gardner T, Sommer AJ, Evan AP, Lingeman JE, Krambeck AE, Worcester EM, El‑Achkar TM and Williams JC Jr: Multimodal imaging reveals a unique autofluorescence signature of Randall's plaque. Urolithiasis. 2021 49: 123‑135.
34. Bouderlique E, Tang E, Perez J, Coudert A, Bazin D, Verpont MC, Duranton C, Rubera I, Haymann JP, Leftheriotis G, et al: Vitamin D and calcium supplementation accelerates Randall's plaque formation in a murine model. Am J Pathol. 2019; 189: 2171‑2180.
35. Yoshihara H, Yamaguchi S and Yachiku S: Effect of sex hormones on oxalate‑synthesizing enzymes in male and female rat livers. J Urol. 1999; 161: 668‑673.
36. Changtong C, Peerapen P, Khamchun S, Fong‑Ngern K, Chutipongtanate S and Thongboonkerd V: In vitro evidence of the promoting effect of testosterone in kidney stone disease: A proteomics approach and functional validation. J Proteomics. 2016; 144: 11‑22.
37. Zhu W, Zhao Z, Chou F, Zuo L, Liu T, Yeh S, Bushinsky D, Zeng G and Chang C: Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR‑185‑5p/CSF‑1 signals. Cell Death Dis. 2019; 10: 275.
38. Sueksakit K and Thongboonkerd V: Protective effects of finasteride against testosterone‑induced calcium oxalate crystallization and crystal‑cell adhesion. J Biol Inorg Chem. 2019 24: 973‑983.
39. Zhu W, Zhao Z, Chou F, Zuo L, Liu T, Yeh S, Bushinsky D, Zeng G and Chang C: Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR‑185‑5p/CSF‑1 signals. Cell Death Dis. 2019; 10: 275.
40. Peerapen P and Thongboonkerd V: Protective cellular mechanism of estrogen against kidney stone formation: A proteomics approach and functional validation. Proteomics. 2019; 19: e1900095.
41. Zhu W, Zhao Z, Chou FJ, Zuo L, Liu T, Bushinsky D, Chang C, Zeng G and Yeh S: The protective roles of estrogen receptor β in renal calcium oxalate crystal formation via reducing the liver oxalate biosynthesis and renal oxidative stress‑mediated cell injury. Oxid Med Cell Longev. 2019: 5305014, 2019.
42. Tian H, Chou FJ, Tian J, Zhang Y, You B, Huang CP, Yeh S, Niu Y and Chang C: ASC‑J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3‑PTK2 signaling. J Exp Clin Cancer Res. 2021; 40: 3.
43. Andy G, John M, Mirna S, Rachita D, Michael K, Maja K, Aseem S and Zeljana B: Controversies in the treatment of androgenetic alopecia: The history of finasteride. Dermatol Ther. 2019; 32: e12647.
44. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014; 192(2): 316-324.
45. Skolarikos A, Straub M, Knoll T, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015; 67(4): 750-763.
46. Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014; 161(9): 659-667.
47. Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians clinical guideline [published correction appears in Ann Intern Med. 2013; 159(3): 230-232]. Ann Intern Med. 2013; 158(7): 535-543.
48. Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: an update. Am Fam Phsician. 2011; 84(11): 1234-1242.